close

Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. The company's product pipeline includes clinical oncology and cardiovascular product candidates in various stages of testing and development. Its principal product includes Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. Abraxis BioScience's other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity; and Coroxane, a nanometer-sized paclitaxel for coronary restenosis and peripheral artery restenosis. It has strategic relationships with Taiho Pharmaceutical Co., Ltd.; Biocon Limited; and ProMetic Life Sciences Inc. Abraxis BioScience also has licensing agreements with Green Cross Corporation and University of Southern California. The company was formerly known as New Abraxis, Inc. and changed its name to Abraxis Bioscience, Inc. in November 2007. Abraxis BioScience is based in Los Angeles, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	78.25
Volume	421142
Volume Avg	104239
52 Week High	78.56
52 Week Low	31.20
PE	N/A
PE (group average)	N/A
EPS Year	-1.88
EPS change Q/Q	-85.11%
EPS change Q/Q Yr ago	-87.72%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-264.9%
REV change Q/Q	5.83%
REV change Q/Q Yr ago	52.62%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%